HydRIS (Hypodermic Rehydration Injection System)
Highly labile products, such as live viral vector vaccines are not particularly suited to a conventional drying process.
HydRIS platform has been proven to be highly successful in stabilising a range of live biologics:
-
Live viral vector vaccines (adeno, MVA)
-
Flavivirus
-
listeria monocytogene based vector
-
Range of live veterinary vaccines
-
Range of extremely labile, protein based therapeutics
ROOM TEMPERATURE STABLE VACCINES:
The long term stability data has shown over 12 months stability at 37°C for the above live vaccines (including adeno and MVA vectors).
cGMP MANUFACTURING CAPABILITY:
-
Nova currently have in-house cGMP manufacturing capability to produce 5,000-10,000 units/batch
-
Our live biologics manufacturing facility is authorised to handle organisms with BSL-1 and BSL-2 categories.
-
The manufacturing process is scalable with the demand.
CLICK on the HydRIS video to see how the technology works.